Phase
Condition
Memory Loss
Alzheimer's Disease
Mental Disability
Treatment
5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
Split-belt treadmill-based locomotor adaptation
5 Sessions of Split-belt treadmill-based locomotor adaptation
Clinical Study ID
Ages 50-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
AD and MCI will be defined through formal diagnosis provided by a board-certifiedNeurologist. Amnestic MCI will be defined using the AD Neuroimaging Initiative (ADNI) criteria. All MCI participants in ADNI are required to have an amnesticsubtype defined as:
Subjective memory concern or a memory problem noted by their partner
Abnormal memory function documented by a specified education adjusted cutoffscore on the delayed paragraph recall of the Anna Thompson story of the LogicalMemory subtest from the Wechsler Memory Scale-Revised
Mini-Mental State Exam (MMSE) score between 20 and 26 (inclusive). Exceptionsmay be made for subjects with less than 8 years of education at the discretionof the PI. (iv) Single or multi-domain amnestic MCI (both subtypes are at highrisk for progression to AD)
Clinical Dementia Rating (CDR) = 0.5 (Memory Box score must be at least 0.5)
General functional performance sufficiently preserved
Evidence of impaired executive function based on Montreal Cognitive Assessment (MoCA) score 13-17
Able to walk 10 or more feet without an assistive device
Completed six grades of education or has a good work history (sufficient to excludeintellectual disabilities)
Not hospitalized within the last 60 days
Exclusion
Exclusion Criteria:
Acute medical illness requiring hospitalization
Uncontrolled congestive heart failure
History of stroke
Inability to perform study procedures
Medical or physical conditions that would preclude participation or walking (e.g.,severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renalfailure, history of angina with activity)
On medications that could adversely affect cognition, eg: antipsychotics, opioids,stimulants, chemotherapy, anti-parkinsonian drugs (eg Levodopa), neurologicprescriptions to treat Multiple sclerosis and/or Parkinson's
Psychotic disorders
Confounding neurologic conditions (e.g., active central nervous system (CNS)opportunistic infections, seizure disorders, head injury with loss of consciousness >30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatricsequelae)
Substance Use Disorder, Major Depressive and Generalized Anxiety Disorders withinsix months of evaluation
Study Design
Study Description
Connect with a study center
Emory Rehabilitation Hospital
Atlanta, Georgia 30322
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.